Video

Dr. Bauml on the Utility of Liquid Biopsy in Metastatic NSCLC

Joshua Bauml, MD, discusses the utility of liquid biopsy in metastatic non–small cell lung cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the utility of liquid biopsy in metastatic non—small cell lung cancer (NSCLC).

Liquid biopsy is frequently used in metastatic disease, says Bauml.

Liquid biopsy may aid in identifying resistance mechanisms in patients who are progressing on targeted therapy, says Bauml. Additionally, the use of liquid biopsy up front could be helpful in the absence of adequate tumor tissue.

An identified alteration from a liquid biopsy is reliable and should be acted upon, explains Bauml. However, physicians should order a tissue biopsy for patients whose liquid biopsy results are negative as the sensitivity of a liquid biopsy is around 70% to 80%.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity